📄 What This Document Is

This is a 6-K filing, which is a report foreign companies like Innate Pharma (based in France) must file with the U.S. SEC to share material news with American investors. Think of it as a formal press release distributed to the financial world. Today's announcement is simple: the company will be participating in an investor conference.

👉 The Core Message: Innate Pharma's executive team will hold one-on-one meetings with investors at the D. Boral Capital Global Conference in New York on May 7, 2026.

🧬 What Innate Pharma Does

In simple terms, Innate Pharma is a clinical-stage biotech company focused on creating new cancer treatments called immunotherapies. These are drugs designed to help the body's own immune system fight cancer more effectively.

• Business Model: They don't have products on the market for sale yet. Their value lies in developing a pipeline of potential drugs and proving they work in clinical trials. They often partner with big pharmaceutical companies to help fund and develop these drugs.
• Listed On: Euronext Paris (Ticker: IPH) and Nasdaq (Ticker: IPHA).

🔬 Their Drug Pipeline

This is the heart of their business. The filing highlights three key potential treatments they are developing, often in collaboration with bigger partners:

1. IPH4502: A "differentiated" antibody-drug conjugate (ADC) being developed for solid tumors. ADCs are like guided missiles that deliver a potent drug directly to cancer cells.
2. Lacutamab: An antibody targeting a protein called KIR3DL2. It is being developed for specific types of skin and peripheral T-cell lymphomas (cancers of the immune system).
3. Monalizumab: An antibody targeting NKG2A. This one is being developed in collaboration with AstraZeneca for non-small cell lung cancer.

🤝 Key Partnerships

Innate doesn't go it alone. They have established important alliances to advance their research and share the financial burden. The filing specifically names:

• AstraZeneca (a collaborator on monalizumab)
• Sanofi

These partnerships add credibility and provide non-dilutive funding to their research efforts.

📅 The Conference Details

While the announcement is brief, the "why it matters" for investors is clear:

• Event: D. Boral Capital Global Conference
• Date: May 7, 2026
• Location: New York, USA
• Innate's Role: Their executive team will be in one-on-one investor meetings.

👉 Why This Matters: For a clinical-stage biotech with no revenue from product sales, constantly telling their story to investors is crucial. These meetings are used to:

• Update potential investors on clinical trial progress.
• Explain the value of their pipeline (the three drugs above).
• Build relationships that could lead to future investment or partnership.

⚠️ Important Risk Factors

The filing includes a standard but critical disclaimer. It points investors to the company's official filings (like the Annual Report on Form 20-F) for a full discussion of risks and uncertainties. Investing in a clinical-stage biotech is inherently risky—most drugs in development never make it to market.

👉 Key Reminder: The company's future depends on the success of its drug trials, regulatory approvals, and its ability to fund operations, all of which are uncertain.

🧠 The Analogy

Think of Innate Pharma as a high-tech startup with several promising prototypes in the lab. They don't have a finished, mass-market product yet. This conference is like them setting up a booth at a major industry trade show—not to sell a product, but to showcase their prototypes to potential investors and strategic partners who can help them fund the massive cost of final testing and manufacturing.

🧩 Final Takeaway

This filing is a straightforward calendar update indicating Innate Pharma's management will be actively networking with investors in early May. For followers of the stock, it signals an opportunity for the company to potentially generate renewed interest in its clinical-stage cancer immunotherapy pipeline, which includes partnerships with giants like AstraZeneca and Sanofi.